ERBB2 and neoplasm: Clinicopathological parameters such as tumour grade, size and nodal burden used in combination with the four immunohistochemical biomarkers oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) and Ki-67, known collectively as IHC4, are generally very effective in determining disease prognosis.